Influence of Catheter-based Renal Denervation in Diseases With Increased Sympathetic Activity

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

Also called NCT01888315

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01888315
Other papers using this trial's data
  • Impact of Renal Denervation on Urinary Peptide-Based Biomarkers in Hypertension Hypertension (Dallas, Tex. : 1979), 2024-06 DOI, PubMed 38572643

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01888315. Non-randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2021-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Influence of Catheter-based Renal Denervation in Diseases With Increased Sympathetic Activity
Condition
Hypertension
Condition
Heart Failure
Condition
Diabetes
Condition
Heart Rhythm Disorders
Intervention (Device)
Renal denervation with Symplicity Flex Medtronic/Ardian
Intervention (Device)
Renal denervation with EnligHTN St. Jude Medical
Intervention (Device)
Renal denervation with Paradise Recor
Intervention (Device)
Renal denervation with V2 Vessix
Lead sponsor
University Hospital, Saarland (class: other)

Record details

Record id
cardio:ct-nct01888315
Content hash
357039a3f1742aef42d4cc2665420f92d74df9cfa3913e549711268d594e54d2